Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials
Shilong Yang, Yan Li, Lianpan Dai, Jianfeng Wang, Peng He, Changgui Li, Xin Fang, Chenfei Wang, Xiang Zhao, Enqi Huang, Changwei Wu, Zaixin Zhong, Fengze Wang, Xiaomin Duan, Siyu Tian, Lili Wu, Yan Liu, Yi Luo, Zhihai Chen, Fangjun Li, Junhua Li, Xian Yu, Hong Ren, Lihong Liu, Shufang Meng, Jinghua Yan, Zhongyu Hu, Lidong Gao, George F. Gao
doi: https://doi.org/10.1101/2020.12.20.20248602
Shilong Yang
1Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., HeFei, China
Yan Li
2CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
Lianpan Dai
2CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
Jianfeng Wang
4National Institute for Food and Drug Control, Beijing, China
Peng He
4National Institute for Food and Drug Control, Beijing, China
Changgui Li
4National Institute for Food and Drug Control, Beijing, China
Xin Fang
3CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
4National Institute for Food and Drug Control, Beijing, China
Chenfei Wang
4National Institute for Food and Drug Control, Beijing, China
Xiang Zhao
4National Institute for Food and Drug Control, Beijing, China
Enqi Huang
1Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., HeFei, China
Changwei Wu
1Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., HeFei, China
Zaixin Zhong
1Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., HeFei, China
Fengze Wang
3CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
Xiaomin Duan
3CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
Siyu Tian
3CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
Lili Wu
3CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
Yan Liu
10Chongqing Medleader Bio-Pharm Co. Ltd., Chongqing, China
Yi Luo
9Beijing Keytech Statistical Technology Co. Ltd., Beijing, China
Zhihai Chen
8Center of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China
Fangjun Li
5Hunan Provincial Center for Diseases Control and Prevention, Changsha, China
Junhua Li
5Hunan Provincial Center for Diseases Control and Prevention, Changsha, China
Xian Yu
6The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
Hong Ren
6The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
Lihong Liu
7Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
Shufang Meng
4National Institute for Food and Drug Control, Beijing, China
Jinghua Yan
3CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
Zhongyu Hu
4National Institute for Food and Drug Control, Beijing, China
Lidong Gao
5Hunan Provincial Center for Diseases Control and Prevention, Changsha, China
George F. Gao
2CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
Article usage
Posted December 22, 2020.
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials
Shilong Yang, Yan Li, Lianpan Dai, Jianfeng Wang, Peng He, Changgui Li, Xin Fang, Chenfei Wang, Xiang Zhao, Enqi Huang, Changwei Wu, Zaixin Zhong, Fengze Wang, Xiaomin Duan, Siyu Tian, Lili Wu, Yan Liu, Yi Luo, Zhihai Chen, Fangjun Li, Junhua Li, Xian Yu, Hong Ren, Lihong Liu, Shufang Meng, Jinghua Yan, Zhongyu Hu, Lidong Gao, George F. Gao
medRxiv 2020.12.20.20248602; doi: https://doi.org/10.1101/2020.12.20.20248602
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials
Shilong Yang, Yan Li, Lianpan Dai, Jianfeng Wang, Peng He, Changgui Li, Xin Fang, Chenfei Wang, Xiang Zhao, Enqi Huang, Changwei Wu, Zaixin Zhong, Fengze Wang, Xiaomin Duan, Siyu Tian, Lili Wu, Yan Liu, Yi Luo, Zhihai Chen, Fangjun Li, Junhua Li, Xian Yu, Hong Ren, Lihong Liu, Shufang Meng, Jinghua Yan, Zhongyu Hu, Lidong Gao, George F. Gao
medRxiv 2020.12.20.20248602; doi: https://doi.org/10.1101/2020.12.20.20248602
Subject Area
Subject Areas
- Addiction Medicine (336)
- Allergy and Immunology (658)
- Anesthesia (177)
- Cardiovascular Medicine (2573)
- Dermatology (218)
- Emergency Medicine (390)
- Epidemiology (12089)
- Forensic Medicine (10)
- Gastroenterology (743)
- Genetic and Genomic Medicine (3994)
- Geriatric Medicine (376)
- Health Economics (667)
- Health Informatics (2578)
- Health Policy (992)
- Hematology (357)
- HIV/AIDS (825)
- Medical Education (396)
- Medical Ethics (107)
- Nephrology (423)
- Neurology (3759)
- Nursing (206)
- Nutrition (559)
- Oncology (1958)
- Ophthalmology (569)
- Orthopedics (233)
- Otolaryngology (301)
- Pain Medicine (247)
- Palliative Medicine (72)
- Pathology (469)
- Pediatrics (1088)
- Primary Care Research (442)
- Public and Global Health (6429)
- Radiology and Imaging (1366)
- Respiratory Medicine (859)
- Rheumatology (394)
- Sports Medicine (336)
- Surgery (431)
- Toxicology (51)
- Transplantation (184)
- Urology (164)